Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9613MR)

This product GTTS-WQ9613MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9613MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4885MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ12888MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ1484MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ10634MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ2346MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ10440MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ159MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ1875MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGEN1884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW